SSX2 and neoplasm: Similarly, when testing for differences between younger and older patient tumors in the prevalence of “high expressing” tumors (normalized gene expression rank ≥75% when compared to pan-tumor control samples) for each of the 64 immune genes, younger patient tumors were less likely to have high expression for 44 genes (69%) and more likely to have high expression for only 2 genes (3%; CXCR2, SSX2) (Supplementary Table 7A).